Testing effectiveness (Phase 2)UnknownNCT05329051
What this trial is testing
Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years
Who this might be right for
SARS-CoV-2 InfectionCOVID-19
Sinocelltech Ltd. 400